Egetis Therapeutics AB (publ)

BATS-CHIXE:EGTXS Stock Report

Market Cap: SEK 1.3b

Egetis Therapeutics Management

Management criteria checks 2/4

Egetis Therapeutics' CEO is Nicklas Westerholm, appointed in Jun 2017, has a tenure of 7.33 years. directly owns 0.083% of the company’s shares, worth SEK1.12M. The average tenure of the management team and the board of directors is 7.3 years and 6.3 years respectively.

Key information

Nicklas Westerholm

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.3yrs
CEO ownership0.08%
Management average tenure7.3yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nicklas Westerholm's remuneration changed compared to Egetis Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-SEK 319m

Mar 31 2024n/an/a

-SEK 327m

Dec 31 2023n/an/a

-SEK 327m

Sep 30 2023n/an/a

-SEK 318m

Jun 30 2023n/an/a

-SEK 286m

Mar 31 2023n/an/a

-SEK 240m

Dec 31 2022SEK 6mSEK 3m

-SEK 194m

Sep 30 2022n/an/a

-SEK 148m

Jun 30 2022n/an/a

-SEK 113m

Mar 31 2022n/an/a

-SEK 114m

Dec 31 2021SEK 5mSEK 3m

-SEK 104m

Sep 30 2021n/an/a

-SEK 147m

Jun 30 2021n/an/a

-SEK 153m

Mar 31 2021n/an/a

-SEK 155m

Dec 31 2020SEK 4mSEK 2m

-SEK 178m

Sep 30 2020n/an/a

-SEK 127m

Jun 30 2020n/an/a

-SEK 134m

Mar 31 2020n/an/a

-SEK 127m

Dec 31 2019SEK 3mSEK 2m

-SEK 61m

Sep 30 2019n/an/a

-SEK 61m

Jun 30 2019n/an/a

-SEK 48m

Mar 31 2019n/an/a

-SEK 46m

Dec 31 2018SEK 3mSEK 2m

-SEK 85m

Sep 30 2018n/an/a

-SEK 95m

Jun 30 2018n/an/a

-SEK 103m

Mar 31 2018n/an/a

-SEK 91m

Dec 31 2017SEK 1mSEK 1m

-SEK 88m

Compensation vs Market: Insufficient data to establish whether Nicklas's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.

CEO

Nicklas Westerholm (48 yo)

7.3yrs

Tenure

SEK 5,900,000

Compensation

Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...

Leadership Team

NamePositionTenureCompensationOwnership
Nicklas Westerholm
Chief Executive Officer7.3yrsSEK 5.90m0.083%
SEK 1.1m
Torsten Almén
Founder18.8yrsno datano data
Ingemar Lundström
Founder18.8yrsno datano data
Louis Ignarro
Founder18.8yrsno datano data
Heidi Brurok
Founder18.8yrsno datano data
Rob Towart
Founder18.8yrsno datano data
Yilmaz Mahshid
Chief Financial Officer3.3yrsno data0.11%
SEK 1.4m
Katayoun Welin-Berger
Vice President of Operations1.6yrsno datano data
Jacques Näsström
Chief Scientific Officerno dataSEK 655.00kno data
Karl Hard
VP and Head of Investor Relations & Communication2.7yrsno datano data
Laetitia Szaller
General Counsel & Head of Complianceless than a yearno datano data
Peter Verwaijen
Global Head of Marketing & Brand Strategy2.4yrsno datano data

7.3yrs

Average Tenure

62yo

Average Age

Experienced Management: EGTXS's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Dart
Member of Scientific Advisory Board6.3yrsno datano data
Mats Blom
Chairman of the Board3.5yrsSEK 300.00k1.07%
SEK 14.4m
Behshad Sheldon
Independent Director1.8yrsno datano data
Thomas Lonngren
Director3.5yrsSEK 600.00k0.097%
SEK 1.3m
Gunilla Osswald
Independent Director7.8yrsSEK 200.00k0.014%
SEK 183.8k
Elisabeth Svanberg
Independent Director7.8yrsSEK 200.00k0.013%
SEK 173.2k
Laura James
Member of Scientific Advisory Board6.3yrsno datano data
James Dear
Member of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

63yo

Average Age

Experienced Board: EGTXS's board of directors are considered experienced (6.3 years average tenure).